Tempus ECG-AF vs VX1+

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Tempus ECG-AF

by Tempus AI, Inc.

VX1+

by Volta Medical

AI Verdict

Tempus ECG-AF is designed for early risk identification of new-onset atrial fibrillation in patients aged 65 or older using ECG analysis. In contrast, VX1+ assists electrophysiologists in real-time during cardiac ablation procedures for existing atrial fibrillation or tachycardia. While both address atrial fibrillation, they serve distinct purposes at different stages of patient care, making them adjacent rather than direct competitors.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is best suited for early risk stratification and guiding preventative care strategies in a general cardiology or geriatric setting, prior to any interventional procedures.

View Tempus ECG-AF →

Choose VX1+ if…

Choose VX1+ if you are an electrophysiologist requiring real-time, AI-powered assistance during active cardiac ablation procedures for atrial fibrillation or atrial tachycardia. This software is designed to help identify abnormal electrograms during the intervention, aiming to improve the precision and efficacy of the ablation process.

View VX1+ →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Tempus ECG-AF	VX1+
Pricing	Contact vendor	Unknown
Deployment	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.	Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

VX1+

VX1+ explicitly highlights a 'simple user interface with color coding' and offers 'real-time manual or automatic annotation,' directly addressing ease of interaction during a complex procedure. Tempus ECG-AF, while integrating into existing systems, is described as operating without a dedicated user interface, suggesting a more backend, automated process.

Clinical Value

VX1+

Both tools offer significant clinical value, but in different contexts. Tempus ECG-AF provides predictive insights for early AF risk stratification, enabling proactive patient management. VX1+ offers real-time, AI-driven guidance during complex cardiac ablation procedures, directly assisting electrophysiologists in improving the precision and potential success of interventions.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF provides clear transparency regarding its financial model, explicitly stating CMS reimbursement availability with a specified Medicare rate. In contrast, VX1+ does not publicly disclose any pricing or reimbursement details, making its economic value proposition less clear for healthcare providers.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for secure and compliant enterprise deployment in healthcare. While VX1+'s compliance is noted as 'expected,' Tempus ECG-AF's explicit affirmations demonstrate a higher level of readiness and transparency for institutional adoption.

Innovation

VX1+

Both tools are innovative. Tempus ECG-AF offers a novel predictive AI for early AF risk detection from standard ECGs. However, VX1+ provides real-time, AI-driven insights directly during a complex interventional procedure, representing a more advanced and interactive application of AI in a critical, live clinical setting.

Support & Docs

VX1+

Both companies offer clear contact points for support. However, Volta Medical explicitly mentions and provides access to a 'VX1u2122 SYSTEM USER MANUAL' which is a strong indicator of comprehensive and readily available operational documentation for its device. Tempus also has a 'Document Library' that includes information for ECG-AF, but the explicit mention of a comprehensive user manual for VX1+ suggests slightly more detailed and accessible operational documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Tempus ECG-AF	VX1+
Product Name	Tempus ECG-AF	VX1+
Primary Purpose	Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.	Assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia.
Target Patient Population/Condition	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, at risk of new onset AF.	Patients undergoing cardiac ablation procedures for Atrial Fibrillation (AF) and Atrial Tachycardia (AT).
Key AI Functionality	AI-based algorithm for 12-lead ECG analysis to detect signs associated with new onset Atrial Fibrillation (AF).	AI-driven insights for real-time manual or automatic annotation of 3D anatomical and electrical maps, identifying spatio-temporal dispersed electrograms (DEs).
Compatibility/Integration	Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.	Compatible with existing 510(k)-cleared catheters and specific data acquisition systems (e.g., Boston Scientific LabSystem Pro, GE HealthCare MacLab CardioLab EP Recording System, Abbott EnSite X 3D mapping system).
Company	Tempus AI, Inc.	Volta Medical

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and VX1+.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools specifically fit into a physician's existing clinical workflow, and what distinct clinical problems do they aim to solve?

Tempus ECG-AF integrates into the workflow of analyzing 12-lead ECGs to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation within 12 months, supporting earlier intervention and follow-up. In contrast, VX1+ provides real-time AI-driven assistance to electrophysiologists directly during cardiac ablation procedures for atrial fibrillation and atrial tachycardia, helping to identify abnormal electrograms to guide treatment.

What is the depth of EHR integration for each tool, particularly regarding automated data flow and documentation of results?

Tempus ECG-AF is designed to integrate into healthcare facility systems, utilizing EHR integrations and patient clinical data to filter eligible patients and likely pushing risk scores or findings back into the EHR via standard communication protocols like APIs. VX1+ integrates with existing EP recording and 3D mapping systems to display real-time annotations and insights on a computer display, which would then need to be documented as part of the procedural report, though specific EHR integration depth is not explicitly detailed.

What evidence supports the accuracy and sensitivity of each tool, and how does this translate into tangible clinical benefits for patients or procedural efficiency?

Tempus ECG-AF is an AI-based algorithm trained on over 1.5 million ECGs, demonstrating a sensitivity of 31% and specificity of 92% for identifying patients at increased risk of new-onset AF within 12 months, aiming for earlier identification and potential prevention of AF-related complications. VX1+ is an AI-powered software that assists in the real-time identification of spatio-temporal dispersed electrograms during ablation procedures, with a 'Booster mode' for increased sensitivity, designed to assist electrophysiologists in targeting areas for more effective procedures, although its clinical significance for ablation outcomes is still being established by investigations.

What is the expected learning curve for physicians and their support staff to become proficient with each tool, and what training resources are provided?

For Tempus ECG-AF, as a software solution integrated into existing systems without a dedicated user interface, the learning curve for physicians is likely focused on interpreting the risk assessment output and integrating it into patient management. VX1+ features a simple user interface with color coding for electrogram dispersion and is designed for real-time interaction during complex procedures, suggesting a moderate learning curve for electrophysiologists to effectively incorporate its AI-driven insights into their ablation strategy, with the company stating it allows for a fast learning curve.

What audit-trail features are available to track the AI's insights, physician interactions, and the impact on clinical decision-making for each tool?

The provided information does not explicitly detail specific audit-trail features for either Tempus ECG-AF or VX1+. However, as medical AI solutions operating within clinical workflows, robust logging of AI outputs and physician actions would be expected for accountability, quality assurance, and to support clinical decision-making processes.

Beyond HIPAA, what specific security measures are in place to protect patient data processed by these AI tools?

Tempus ECG-AF's developer, Tempus, employs a defense-in-depth security strategy beyond HIPAA, including rigorous de-identification processes, high-level encryption for data in transit and at rest in secure cloud environments, and strict access controls for authorized personnel. For VX1+, specific security measures beyond general HIPAA compliance expectations for medical devices used in U.S. healthcare settings are not explicitly detailed in the provided information.

What are the key considerations for a multi-site healthcare system looking to roll out either of these AI tools across different facilities?

For Tempus ECG-AF, multi-site rollout would involve standardizing ECG acquisition and ensuring seamless data integration with existing healthcare facility systems and EHRs across different locations, as demonstrated by deployments in large health systems. For VX1+, key considerations would include consistent integration with various existing EP recording and 3D mapping systems found in different EP labs, along with comprehensive training for electrophysiology teams across multiple sites to ensure standardized use of its real-time procedural guidance.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Tempus ECG-AF or VX1+

Backers

Who funded each tool's parent company.